{"id":"W2804803500","doi":"10.1200/edbk_200679","title":"New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?","year":2018,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Pembrolizumab; Nivolumab; Hodgkin lymphoma; Clinical trial; Intensive care medicine; Disease; Oncology; Lymphoma; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007009859,0.0006494217,0.00567651,0.00011161,0.00007101934,0.00001280195,0.000307253,0.0007342048,0.00159778],"category_scores_gemma":[0.0005739263,0.0004284599,0.002884313,0.0005425837,0.001400604,0.00006908398,0.0001046686,0.0002848186,0.000374316],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003431681,"about_ca_system_score_gemma":0.03778221,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001384701,"about_ca_topic_score_gemma":0.00005016199,"domain_scores_codex":[0.9947483,0.000462954,0.002812025,0.001033877,0.0004357446,0.0005071166],"domain_scores_gemma":[0.9883897,0.008116794,0.001904524,0.0007292786,0.0002458337,0.0006138345],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00011746,0.006109913,0.001585901,0.000429439,0.001336841,0.00001918866,0.0002179473,4.609155e-8,1.333942e-8,0.0001052191,0.2249841,0.765094],"study_design_scores_gemma":[0.00460399,0.007499285,0.01033236,0.001596129,0.002326894,0.0001289163,0.0001919664,0.000003835033,7.564957e-7,0.00007305706,0.9729078,0.0003349983],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002719554,0.9724347,0.00001205689,0.01793575,0.0009473242,0.001813829,0.00008739975,0.00003365018,0.006463339],"genre_scores_gemma":[0.00001279207,0.9012047,0.032552,0.005935268,0.002654658,0.0006175271,0.000419803,0.00005846619,0.05654481],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7647589,"threshold_uncertainty_score":0.9998167,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2095668149700712,"score_gpt":0.5368109536088498,"score_spread":0.3272441386387785,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}